On the Record · Takeda Pharmaceutical
Takeda Pharmaceutical acquisitions, on the record
The businesses Takeda Pharmaceutical bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Nimbus Lakshmi, Inc.Word for word“For example, on February 8, 2023, we acquired all of the capital stock of Nimbus Lakshmi, Inc., a wholly owned subsidiary of Nimbus Therapeutics, LLC, that owns or controls the intellectual property rights and other associated assets related to TAK-279, the allosteric TYK2 inhibitor known internally at Nimbus as “NDI-034858”.” 20-F for 2024 | acquisition | — | — |
Shire plcWord for word“As examples of acquisition activities, in January 2019, we acquired Shire plc., bringing together Takeda and Shire’s complementary positions in gastroenterology and neuroscience, and establishing leading positions in rare diseases and PDT.” 20-F for 2024 | acquisition | January 2019 | — |
Millennium Pharmaceuticals, Inc.Word for word“In 2008, we acquired a leading U.S. biopharmaceutical company in Millennium Pharmaceuticals, Inc.” 20-F for 2024 | acquisition | 2008 | — |
NycomedWord for word“Takeda also acquired Nycomed in 2011, with a strong presence in Europe and emerging markets.” 20-F for 2024 | acquisition | 2011 | — |
TiGenix NVWord for word“Takeda acquired the rights to ALOFISEL via its acquisition of TiGenix NV in 2018.” 20-F for 2024 | acquisition | 2018 | — |
Teijin Pharma LimitedWord for word“In April 2021, we completed the asset transfer associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited for a total value of JPY 133.0 billion.” 20-F for 2024 | divestiture | April 2021 | JPY 133.0 billion |
Hasten Biopharmaceutic Co., Ltd.Word for word“In March 2022, we completed the sale of a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. ” 20-F for 2024 | divestiture | March 2022 | — |
Nimbus Lakshmi, Inc. (wholly owned subsidiary of Nimbus Therapeutics, LLC)Word for word“For example, on February 8, 2023, we acquired all of the capital stock of Nimbus Lakshmi, Inc., a wholly owned subsidiary of Nimbus Therapeutics, LLC, that owns or controls the intellectual property rights and other associated assets related to TAK-279, the allosteric TYK2 inhibitor known internally at Nimbus as “NDI-034858”.” 20-F for 2025 | acquisition | February 8, 2023 | — |
Teva Takeda Pharma Ltd. (joint venture business in Japan, shares in associate)Word for word“During the fiscal year ended March 31, 2025, Takeda decided to enter into discussions with Teva Pharmaceutical Industries Ltd. to dissolve a joint venture business in Japan primarily focused on generic medicines and long-listed products.” 20-F for 2025 | divestiture | During the fiscal year ended March 31, 2025 | — |
Maverick Therapeutics Inc.Word for word“The impairment charges in the fiscal year ended March 31, 2025 include JPY 27.8 billion resulting from the decision to terminate the development of TAK-186 and TAK-280 acquired through Maverick Therapeutics Inc.” 20-F for 2025 | acquisition | — | — |
Read from Takeda Pharmaceutical’s annual reports (20-F for 2026, 20-F for 2025, 20-F for 2024) and the financial data it files with the SEC, as of 2026-06-17. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.